Global Stem Cell Industry - China Biotechnology Market

Global and China Stem Cell Industry 2014-207 Market Trend, Size, Share, Growth and Forecast : Industry Analysis, Overview, Research and Development - Market Research Reports.Biz

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatment of cardiovascular diseases, leukemia (a kind of hematological system disease), nervous system diseases, damage or lesion of liver, kidney and other parenchymal organs, etc..

Currently, cord blood bank is the fastest-growing and relatively mature market amid stem cell upstream sectors and even the whole industry chain. In 2005, there were 23 cord blood banks worldwide and in 2013 the figure exceeded 480. Global cord blood stem cell (CBSC) storage companies can be roughly divided into two categories: the ones running in a globalized business model, such as Cryo-Cell International and Esperite (formerly known as Cryo-Save Group), and the others giving priority to regional operation e.g. Zhongyuan Union Stem Cell Bioengineering (VCANBIO), Golden Meditech and LifeCell International. However, the companies mainly engaged in cord blood bank business are currently small in scale, only a few with more than 500,000 clients.

The stem cell technology and product research-oriented midstream sector is in its infancy, mostly concentrated in few countries like Europe, America and South Korea. At present, most companies in the industry chain are basically in the red for years running due to huge R&D costs. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. capital subsidy) and the capital support of significant cooperative partners, very few companies have dropped out.

We can provide sample pages for the better understanding of this report. Request Sample of This Report, kindly Visit at Global and China Stem Cell Industry Report, 2014-2017

Up to now, altogether 9 sorts of stem cell products have been approved worldwide, 3 of which are in the category of stem cell drugs developed by S. Korean companies, such as MEDIPOST’s adult stem cell drug CARTISTEM for osteoarthritis treatment and the stem cell product Prochymal (MEDIPOST obtained the product via acquiring the Therapeutics business of Osiris Therapeutics) direct at treating children suffering acute graft-versus-host disease (GVHD).

In the meantime, traditional pharmaceutical giants like Novartis are setting about quickly accessing the field through mergers and acquisitions. On Aug. 19, 2014, Novartis reached an acquisition agreement with Gamida Cell (a corporate dedicated to stem cell technology R&D and its application in stem cell transplantation for leukemia patients), which specified that Novartis spend USD35 million in acquiring 15% equity in the latter and win the option to take over the remaining equity in two years with USD165 million; in Sep. 2013, Novartis also entered a cooperation with Regenerex to jointly develop the hematopoietic Stem Cell platform FCRx of the latter.

Table of Content

1. Overview of Stem Cell Industry
1.1 Definition
1.2 Classification & Application
1.3 Industry Chain
1.4 Development Course

2. Global Stem Cell Industry Chain
2.1 Industry Chain Layout of Major Enterprises
2.2 Policy
2.3 Development
2.4 Upstream

3. China Stem Cell Industry Chain
3.1 Development Introduction
3.2 Policy Environment
3.3 Upstream

4. Upstream Enterprises
4.1 Cryo-Cell International
4.1.1 Profile
4.1.2 Operation
4.1.3 Cord Blood Business

5. Midstream and Downstream Enterprises
5.1 NeoStem
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 R&D
5.1.5 Stem Cell Business

Latest Reports (Same Publisher):

Global and China PTCA Balloon Market Investment Report, 2014-2016 Industry Trend, Size, Share, Growth and Forecast : Industry Analysis, Overview, Research and Development - Market Research Reports.Biz

PTCA balloon, as a indispensable medical device in percutaneous coronary intervention (PCI), serves not only as a delivery system for stent, but also as a device for pre-/post-stent dilatations. Therefore, the development of PTCA balloon industry is closely related to that of PCI.

As national economy develops and people’s living standard improves, the number of patients receiving PCI has been on the rise year by year, and totaled 454,505 cases in China in 2013, up 16.9% from a year earlier. Demand for PTCA balloon during the same period reached 1.186 million sets, rising by 13.8% on a year-on-year basis.

We can provide sample pages for the better understanding of this report. Request Sample of This Report, kindly Visit at China PTCA Balloon Market Investment Report, 2014-2016

MicroPort is a bellwether in the Chinese coronary stent system market. On Jan. 20, 2014, MicroPort announced that it would acquire drug-eluting stent-related assets of Cordis under Johnson & Johnson. After the acquisition is completed, MicroPort’s share in drug-eluting stent market will rise by over 10%. This will also promote company’s business development of PTCA balloon for delivering coronary stent. MicroPort now can manufacture more than 200,000 sets of PTCA balloon annually.